Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 3/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 4/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.37 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13997534 | 0.91 | NPY4R (0.48) | NPY4RTGM2FPR2AVPR2CHRM1 | |
| SCHEMBL13997532 | 0.77 | NPY4R (0.47) | NPY4RTGM2FPR2AVPR2CHRM1 | |
| SCHEMBL17244044 | 0.71 | POLA1 (0.62) | PLA2G2APOLA1 | |
| SCHEMBL26033570 | 0.70 | POLA1 (0.59) | PLA2G2APOLA1 | |
| SCHEMBL19115392 | 0.70 | POLA1 (0.61) | PLA2G2APOLA1 | |
| SCHEMBL10237707 | 0.70 | POLA1 (0.53) | PLA2G2AEPHA2POLA1 | |
| SCHEMBL10237709 | 0.70 | POLA1 (0.53) | PLA2G2AEPHA2POLA1 | |
| SCHEMBL10237713 | 0.70 | POLA1 (0.53) | PLA2G2AEPHA2POLA1 | |
| SCHEMBL17212338 | 0.69 | POLA1 (0.54) | PLA2G2AEPHA2POLA1 | |
| SCHEMBL17212336 | 0.69 | POLA1 (0.54) | PLA2G2AEPHA2POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080317767-A1 | Tripartitle Raftophilic Strutures and their Use | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317767-A1 | Tripartitle Raftophilic Strutures and their Use | FGB, CLTB, CD38 | NPY4R 2249/4885TGM2 2625/4885FPR2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.